Clinical trial · no report yet · Phase 1/Phase 2
NCT06445062
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT06445062 ↗
- Recruiting
- Revolution Medicines, Inc.
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- RMC-6236; mFOLFOX6 regimen; bevacizumab; mFOLFIRINOX regimen; cetuximab; gemcitabine; nab-paclitaxel; RMC-9805; FOLFIRI regimen
- Arms
- Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol C: metastatic PDAC · Experimental
- Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol F: RAS G12D-mutated metastatic PDAC · Experimental
- Subprotocol G: RAS G12D-mutated metastatic CRC · Experimental
- Enrollment
- 1,130 (estimated)
- Primary outcomes
- Adverse events (Subprotocols A-F)
- Dose limiting toxicities (Subprotocols A-F)
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)
- Sponsor
- Revolution Medicines, Inc.
- Start
- May 24, 2024
- Primary completion
- Sep 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06445062 · updated Sep 22, 2026
Publications
linked from the registry- Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8. PubMed 40056080